Event Data
{"article_title":"Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.","author":"Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH","journal_title":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","issn":"1537-6591","isbn":"","publication_date":"2021-09-07","volume":"73","issue":"5","first_page":"e1029","page_count":"","accession_number":"34164674","doi":"","publisher":"Oxford University Press","doctype":"Journal Article","subjects":"Clostridioides difficile; Clostridium Infections drug therapy; Clostridium Infections epidemiology; Communicable Diseases; Adult; Clostridioides; Delivery of Health Care; Humans","interest_area":["Infectious Disease & Vaccines"],"abstract":"This clinical practice guideline is a focused update on management of Clostridioides difficile infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for the treatment of CDI. This guideline was developed by a multidisciplinary panel representing the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA). This guideline is intended for use by healthcare professionals who care for adults with CDI, including specialists in infectious diseases, gastroenterologists, hospitalists, pharmacists, and any clinicians and healthcare providers caring for these patients. The panel's recommendations for the management CDI are based upon evidence derived from topic-specific systematic literature reviews. Summarized below are the recommendations for the management of CDI in adults. The panel followed a systematic process which included a standardized methodology for rating the certainty of the evidence and strength of recommendation using the GRADE approach (Grading of Recommendations Assessment, Development, and Evaluation). A detailed description of background, methods, evidence summary and rationale that support each recommendation, and knowledge gaps can be found online in the full text. \u00a9 The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=34164674","isPdfLink":true,"isSAML":false,"an":"34164674","number_other":"","type_pub":"","issn_electronic":"1537-6591","languages":"English","language":"eng","date_entry":"","date_update":"","titleSource":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2021 Sep 07; Vol. 73 (5), pp. e1029-e1044.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2021-09-07","description":"This clinical practice guideline is a focused update on management of Clostridioides difficile infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for the treatment of CDI. This guideline was developed by a multidisciplinary panel representing the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA). This guideline is intended for use by healthcare professionals who care for adults with CDI, including specialists in infectious diseases, gastroenterologists, hospitalists, pharmacists, and any clinicians and healthcare providers caring for these patients. The panel's recommendations for the management CDI are based upon evidence derived from topic-specific systematic literature reviews. Summarized below are the recommendations for the management of CDI in adults. The panel followed a systematic process which included a standardized methodology for rating the certainty of the evidence and strength of recommendation using the GRADE approach (Grading of Recommendations Assessment, Development, and Evaluation). A detailed description of background, methods, evidence summary and rationale that support each recommendation, and knowledge gaps can be found online in the full text.<br \/> (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=34164674&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH","header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"34164674","RelevancyScore":"898","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"897.511047363281"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=34164674&authtype=shib&custid=ns346513&group=main&profile=eds","physicalDescription":{"Pagination":{"StartPage":"e1029"}},"additionalInfo":{"Authored_By":"Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH","Journal_Info":"Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE","Publication_Type":"Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't","Published_Date":"2021-09-07","Source":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2021 Sep 07; Vol. 73 (5), pp. e1029-e1044.","Languages":"English","Electronic_ISSN":"1537-6591","MeSH_Terms":"Clostridioides difficile* , Clostridium Infections*\/drug therapy , Clostridium Infections*\/epidemiology , Communicable Diseases*, Adult ; Clostridioides ; Delivery of Health Care ; Humans","Subjects":"Adult, Clostridioides, Delivery of Health Care, Humans, Clostridioides difficile, Clostridium Infections drug therapy, Clostridium Infections epidemiology, Communicable Diseases","Title_Abbreviations":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","Volume":"73"}}
Additional Info
["Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH","Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE","Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't","2021-09-07","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2021 Sep 07; Vol. 73 (5), pp. e1029-e1044.","English","1537-6591","Clostridioides difficile* , Clostridium Infections*\/drug therapy , Clostridium Infections*\/epidemiology , Communicable Diseases*, Adult ; Clostridioides ; Delivery of Health Care ; Humans","Adult, Clostridioides, Delivery of Health Care, Humans, Clostridioides difficile, Clostridium Infections drug therapy, Clostridium Infections epidemiology, Communicable Diseases","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","73"]
Description
This clinical practice guideline is a focused update on management of Clostridioides difficile infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for the treatment of CDI. This guideline was developed by a multidisciplinary panel representing the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA). This guideline is intended for use by healthcare professionals who care for adults with CDI, including specialists in infectious diseases, gastroenterologists, hospitalists, pharmacists, and any clinicians and healthcare providers caring for these patients. The panel's recommendations for the management CDI are based upon evidence derived from topic-specific systematic literature reviews. Summarized below are the recommendations for the management of CDI in adults. The panel followed a systematic process which included a standardized methodology for rating the certainty of the evidence and strength of recommendation using the GRADE approach (Grading of Recommendations Assessment, Development, and Evaluation). A detailed description of background, methods, evidence summary and rationale that support each recommendation, and knowledge gaps can be found online in the full text.<br /> (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
